The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Sustained viral response (SVR) significantly improves the prognosis in patients with hepatitis C virus (HCV) chronic infection but does not totally alleviate the risk of liver‐related complications (LRC). We aimed to evaluate whether the dynamics of multiple measurements of simple parameters after SVR enable the development of a personalized prediction of prognosis in HCV patients. HCV mono‐infected...
Résumé Le traitement de référence de l’hépatite chronique virale C reste, dans l’attente de la commercialisation de deux antiprotéases (télaprevir, bocéprevir), une association d’interféron pégylé α-2a ou α-2b et de ribavirine [1, 2, 3]. Ce traitement «conventionnel» permet d’obtenir un taux moyen de guérison de 40 % chez les malades infectés par une souche de génotype 1 [3] et de 70 % chez les malades...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.